

QUARTERLY INVESTOR CALL

Investor call at 9.00am AEDT, Wednesday 25 January 2023 to discuss Quarterly Results and Business Outlook

Adelaide, Australia, 19 January 2023: Australian medical technology company LBT Innovations Limited (ASX: LBT) (**LBT** or the **Company**), a leader in medical technology automation using artificial intelligence, announces that the Company will hold an investor conference call at **9.00am AEDT on Wednesday 25 January 2023** to discuss the Company's activities and financial results for the Quarter ended 31 December 2022. The call will be hosted by the Company's CEO and Managing Director, Brent Barnes, and will include an update on the market for opportunity for the Company's new APAS® Pharma product.

How to Access the Investor Call

All attendees must register to attend the call. After registering, you will receive a confirmation email about joining the webinar including options to attend via computer or telephone.

Please register using the following link:

https://us06web.zoom.us/webinar/register/WN_LpU3X1TvQ1muOkWnfFSpBw

A Q&A session will be held at the end of the conference call, in order to participate in this, you will need to join the conference via computer. A recording of the call will be available on the Investor Centre section of the Company's website for 60 days after the call.

Accessing the Call after the event

A recording of the call will be available on the Investor Centre section of the Company's website for 60 days after the call.

Approved for release by the Chair of the LBT Board.

– ENDS –

About LBT Innovations

LBT Innovations (LBT) improves patient outcomes by making healthcare more efficient. Based in Adelaide, South Australia, the Company has a history of developing world leading products in microbiology automation. Its first product, MicroStreak®, was a global first in the automation of culture plate specimen processing. The Company's second product, the Automated Plate Assessment System (APAS® Independence) uses LBT's intelligent imaging and machine learning software to automate the imaging, analysis and interpretation of culture plates following incubation. The technology remains the only US FDA-cleared artificial intelligence technology for automated culture plate reading and is being commercialised through LBT's wholly owned subsidiary Clever Culture Systems AG (CCS). Thermo Fisher Scientific, Inc is exclusive distributor of the APAS® Independence in the United States and selected countries in Europe.

INVESTOR ENQUIRIES

LBT Innovations
Brent Barnes Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: info@lbtinnovations.com